Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum Refractory Epithelial Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT04921527
What this trial is testing

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Ovarian CancerRelapsed or RefractoryChiauranib+1 more
Chipscreen Biosciences, Ltd. 454
Early research (Phase 1)Ended earlyNCT01227941
What this trial is testing

MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011)

Who this might be right for
Ovarian Cancer
Tesaro, Inc. 6
Testing effectiveness (Phase 2)Study completedNCT00189345
What this trial is testing

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Who this might be right for
Ovarian CancerFallopian Tube NeoplasmsPeritoneal Neoplasms
AGO Study Group 44
Testing effectiveness (Phase 2)Study completedNCT00097019
What this trial is testing

Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

Who this might be right for
Ovarian Cancer
Genentech, Inc. 53
Testing effectiveness (Phase 2)Study completedNCT00543049
What this trial is testing

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

Who this might be right for
Platinum Refractory Epithelial Ovarian CancerPrimary Cancer of the PeritoneumCancer of the Fallopian Tube
AGO Study Group 73
Testing effectiveness (Phase 2)Active Not RecruitingNCT01012817
What this trial is testing

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 88
Early research (Phase 1)Looking for participantsNCT06234423
What this trial is testing

CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Who this might be right for
Ovarian CancerSolid Tumor
OnCusp Therapeutics, Inc. 263
Testing effectiveness (Phase 2)Ended earlyNCT04019288
What this trial is testing

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
M.D. Anderson Cancer Center 12
Testing effectiveness (Phase 2)Ended earlyNCT01296035
What this trial is testing

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Women and Infants Hospital of Rhode Island 8
Testing effectiveness (Phase 2)Study completedNCT05130515
What this trial is testing

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.

Who this might be right for
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 6
Testing effectiveness (Phase 2)Looking for participantsNCT05983276
What this trial is testing

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Who this might be right for
Ovarian Cancer
Loyola University 40
Large-scale testing (Phase 3)Not Yet RecruitingNCT06867562
What this trial is testing

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

Who this might be right for
Platinum-Resistant Primary Peritoneal CarcinomaPlatinum Resistant High Grade Epithelial Ovarian CancerPlatinum Resistant High Grade Serous Ovarian Cancer
Jina Pharmaceuticals Inc. 166
Testing effectiveness (Phase 2)Study completedNCT00003523
What this trial is testing

Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT00189358
What this trial is testing

A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

Who this might be right for
Ovarian CancerCancer of the Fallopian TubePeritoneal Cancer
AGO Study Group
Testing effectiveness (Phase 2)Ended earlyNCT04718675
What this trial is testing

KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Who this might be right for
Relapsed Solid TumorsRefractory Solid TumorsNon-Hodgkin Lymphoma+2 more
Kronos Bio 135
Large-scale testing (Phase 3)Ended earlyNCT04729387
What this trial is testing

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Who this might be right for
Ovarian Cancer
Novartis Pharmaceuticals 358
Testing effectiveness (Phase 2)Study completedNCT00006028
What this trial is testing

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Large-scale testing (Phase 3)Study completedNCT00057720
What this trial is testing

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Telik 440
Testing effectiveness (Phase 2)Study completedNCT02591095
What this trial is testing

ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant or Refractory Ovarian Cancer
Centre Francois Baclesse 47
Testing effectiveness (Phase 2)Study completedNCT00036751
What this trial is testing

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial Cancer+1 more
National Cancer Institute (NCI) 40
Next Page